Physician profile
Michael S Babula
NPI 1043988413
$2,795.99
in general payments reported to CMS, 2019-2025
23 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $719 · 2023: $932 · 2024: $426 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $524.61 | 2022-2024 | Caplyta |
| Glaxosmithkline, LLC. | $453.27 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $255.96 | 2022-2024 | |
| Gilead Sciences, INC. | $214.50 | 2022-2025 | |
| Boston Scientific Corporation | $202.07 | 2021 | |
| Pfizer INC. | $149.77 | 2023-2025 | |
| Lilly USA, LLC | $144.63 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $136.99 | 2022-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $113.44 | 2022-2024 | |
| Shield Therapeutics INC | $112.92 | 2023-2025 | Accrufer |
| Amgen INC. | $84.75 | 2021-2022 | |
| Exact Sciences Corporation | $64.20 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $57.42 | 2022 | |
| Merck Sharp & Dohme LLC | $38.45 | 2023-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Novartis Pharmaceuticals Corporation | $37.22 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.42 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.53 | 2024-2025 | Jardiance, Synjardy |
| Idorsia Pharmaceuticals US INC | $33.01 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $23.55 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $23.28 | 2025 | |
| Electromed, INC. | $23.01 | 2024 | Smartvest |
| Grifols USA, LLC | $20.29 | 2022 | |
| Bardy Diagnostics, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Babula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.